We’re proud to announce a $200 million private financing to fuel the next chapter for Star Therapeutics.
Building on the momentum of this year, including the acquisition of Star subsidiary Vega Therapeutics, this financing will support our next-generation pipeline as we advance preclinical programs into the clinic and continue expanding into new areas of significant unmet need.
Our mission hasn’t changed: developing best-in-disease therapies for the millions of patients who need them. Listen in below as CEO Adam Rosenthal shares details. Read more here. star-therapeutics.com/star-therapeut…
Building on the momentum of this year, including the acquisition of Star subsidiary Vega Therapeutics, this financing will support our next-generation pipeline as we advance preclinical programs into the clinic and continue expanding into new areas of significant unmet need.
Our mission hasn’t changed: developing best-in-disease therapies for the millions of patients who need them. Listen in below as CEO Adam Rosenthal shares details. Read more here. star-therapeutics.com/star-therapeut…
1:33